Coeptis Therapeutics, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced of an exclusive option agreement involving the intellectual property rights to three technologies jointly developed in the laboratories of Jason Lohmueller, Ph.D., Assistant Professor of Immunology; Alexander Deiters, Ph.D., and Professor of Chemistry; and Olivera Finn, Ph.D., Professor of Immunology.